Revolutionizing in vivo genome editing with targeted, non-viral delivery

On August 8, 2024, David McCall, Senior Editor, BioInsights, spoke to Vesigen Therapeutics’ Joseph Nabhan, Chief Scientific Officer, Gary Hao, Vice President, CMC, and Qin Yu, Vice President, Research, about the potential for novel vesicular delivery platforms to enhance the genome editor delivery toolkit and enable the expansion of in vivo gene editing therapeutics into new tissues and indications. This Viewpoint article is based on that conversation.

Please enter your email to access content Read now